ClinicalTrials.gg
TerminatedNCT00174382Updated Mar 24, 2015Results posted

Vaspect Study - An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia

A Phase 3 interventional study of Donepezil in Dementia, Vascular and Dementia, Mixed, sponsored by Pfizer. Terminated at 30 sites in Canada. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2015-03-24.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Why this study was terminated
See Detailed Description

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
149
Allocation
Non-randomized
Ages
50 Years and older
Sex
All
01

Study summary

To document effectiveness, safety, and tolerability of donepezil in patients with mixed AD/VaD, and to further document the effectiveness, safety, and tolerability of donepezil in patients with VaD. The effects of donepezil on executive functioning, behavior, general cognition, ADLs and global functioning will be assessed.

Read the detailed description

The trial was terminated on October 15, 2007 due to difficulties in recruiting the subjects. There were no safety or efficacy concerns regarding the study medication in the decision to terminate the trial.

02

Conditions studied

  • Dementia, Vascular
  • Dementia, Mixed
03

In context

Dementia, Vascular

183 studies on the registry are indexed under Dementia, Vascular; 42 are open to participants now.

This study's enrollment of 149 is above the median of 123 across 116 interventional studies indexed under Dementia, Vascular.

Browse Dementia, Vascular studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must meet criteria for the clinical diagnosis of Vascular Dementia or the clinical diagnosis of dementia due to multiple etiologies.
  • Subjects must have a reliable caregiver or family member who agrees to accompany the subject to all scheduled visits, provide information about the subject as required.

Exclusion criteria

Exclusion Criteria:

  • Subjects with any current primary psychiatric diagnosis other than dementia of the Alzheimer's type or Vascular Dementia.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
149 participants (actual)

Study arms

  • Experimental
    1

    Drug: Donepezil

Interventions

  • donepezil 5mg/day for 6 weeks and then 5 to 10mg/day for 18 weeks

06

What researchers measure

Primary outcomes

  1. Change in Total Score of Standardized Mini-Mental State Examination (sMMSE); Full Analysis Set

    Change from baseline in sMMSE total score. Change: mean total score at observation minus mean total score at baseline. Total score is derived by adding all subscores and ranges from 0 to 30; a higher score indicates a better cognitive state.

    Time frame: Baseline, week 12, week 24

Secondary outcomes

  1. Disability Assessment for Dementia Change From Baseline; Activities of Daily Living (ADL) Domain.

    The ADL domain includes 17 yes/no questions on four items (hygiene, dressing, continence, eating). Score equals number of questions answered yes multiplied by 100 divided by number of questions answered. Change: Mean ADL score at observation minus mean ADL score at baseline.

    Time frame: Baseline, week 12, week 24

  2. Disability Assessment for Dementia Change From Baseline; Instrumental ADL (IADL) Domain.

    IADL domain consists of 23 yes-no questions on 6 items (meal preparation, telephoning, going out, finance \& correspondence, medications, leisure \& housework. Change: Mean IADL score at observation minus mean IADL score at baseline. Total IADL score = number of questions answered yes multiplied by 100 divided by total number of questions answered

    Time frame: Baseline, 12 weeks, 24 weeks

  3. Disability Assessment for Dementia (DAD) Change From Baseline Total Score; Full Analysis Set (FAS)

    DAD total score equals total number of questions answered yes multiplied by 100 divided by total number of questions answered.

    Time frame: Baseline, week 12, week 24

  4. Free-hand Drawing Test (CLOX 1) Change From Baseline; Full Analysis Set (FAS)

    The ability to draw a clock free-hand. Scored on a scale from 1 to 15; lower scores indicate higher impairment. Change: Mean CLOX 1 score at observation minus mean CLOX score at baseline.

    Time frame: Baseline, 12 weeks, 24 weeks

  5. Copied Clock Drawing Test (CLOX 2) Change From Baseline; Full Analysis Set (FAS)

    The ability to copy a drawing of a clock. Scored on a scale from 1 to 15; lower scores indicate higher impairment. Change: Mean CLOX 2 score at observation minus mean CLOX 2 score at baseline.

    Time frame: Baseline, 12 weeks, 24 weeks

  6. CLOX Differential Score Change From Baseline; Full Analysis Set (FAS)

    CLOX differential score equals the difference between the score for CLOX 2 and the score for CLOX 1, values range from 15 to 0, with 0 indicating perfect executive function, and a worsening with the increasing score.

    Time frame: Baseline, 12 weeks, 24 weeks

  7. Phonectic Fluency Total Score From Baseline; Full Analysis Set (FAS)

    The number of words a particpant can generate in 1 minute.

    Time frame: Baseline, 12 weeks, week 24

  8. Neuropsychiatric Inventory Questionnaire (NPI-Q) Score Change From Baseline; Full Analysis Set (FAS)

    NPI-Q measures severity of behavioural manifestations of dementia \& the level of distress each symptom gives the main caregiver, 1 (mild), 3 (severe), 0 if symptom absent, NPI-Q also measures the caregiver distress associated with each symptom,0(no distress)to 5(very severe), total score equals sum of individual item scores \& ranges from 0 to 36

    Time frame: Baseline, 12 weeks, 24 weeks

  9. Neuropsychiatric Inventory Questionnaire Distress (NPI-Q-D) Score Change From Baseline; Full Analysis Set (FAS)

    The total NPI-Q-D score is equal to the sum of all indiviudal symptom distress scale scores with a range of 0 to 60

    Time frame: Baseline, week 12, week 24

  10. Clinical Global Impressions Severity Score (CGI-S) Clinical Global Impressions Severity Score Improvement(CGI-I)Change From Baseline, Full Analysis Set (FAS)

    Scale measures subject's clinical condition at baseline for severity (CGI-S) \& for improvement from baseline (CGI-I). At baseline subject rated on numerical scale, 1 (not at all ill) to 7 (most extremely ill). At follow up subject rated on 7 point Likert scale from 1(very much improved) to 7(very much worse) \& 4 indicates no change from baseline

    Time frame: Baseline, week 24

  11. Clinical Global Impressions Severity (CGI-S)

    Scale measures subject's clinical condition at baseline for severity (CGI-S) subject rated on numerical scale, 1 (not at all ill) to 7 (most extremely ill).

    Time frame: Baseline

  12. Clinical Global Impressions Improvement (CGI-I)

    Scale measures subject's clinical condition for improvement from baseline (CGI-I)subject rated on 7 point Likert scale from 1(very much improved) to 7(very much worse) \& 4 indicates no change from baseline

    Time frame: Week (wk) 24

  13. Clinical Global Impressions Improvement (CGI-I) Dichotomized Response

    Scale measures subject's (CGI-I) rated on categorial 7 point Likert scale 1 (very much improved) to 7 (very much worse) with 4 indicating no change from baseline. A dichotomized variable was created: responder = CGI-I score of 4 or less; non-responder = CGI-I score of 5 or more

    Time frame: Baseline, week 24

07

Results

Posted Jun 12, 2009

Participant flow

Study was conducted in Canada in 30 centres.

Participant flow — Overall Study
MilestoneDonepezil
Started149
Completed116
Not completed33
Withdrew: Death2
Withdrew: Adverse event19
Withdrew: Withdrawal by subject6
Withdrew: Protocol violation3
Withdrew: Arrived early for last visit in error1
Withdrew: Subject felt pill not effective enough1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryChange in Total Score of Standardized Mini-Mental State Examination (sMMSE); Full Analysis Set

Change from baseline in sMMSE total score. Change: mean total score at observation minus mean total score at baseline. Total score is derived by adding all subscores and ranges from 0 to 30; a higher score indicates a better cognitive state.

Time frame:
Baseline, week 12, week 24
Reported as:
Mean · Score on a scale
Change in Total Score of Standardized Mini-Mental State Examination (sMMSE); Full Analysis Set
Score on a scaleDonepezil
Week 12 (n=124)0.41 ± 3.10
Week 24 (n=114)0.69 ± 3.2
Week 24 LOCF (n=137)0.48 ± 3.25
Statistical analysis
  • Donepezil · Mixed Models Analysis · p = 0.182 (Baseline value, center, and week as fixed effects; subject was included as a random effect.) · Mean difference (net): 0.44 · 95% CI -0.21 to 1.09
  • Donepezil · Mixed Models Analysis · p = 0.067 · Mean difference (net): 0.66 · 95% CI -0.05 to 1.36
  • Donepezil · Mixed Models Analysis · p = 0.085
SecondaryDisability Assessment for Dementia Change From Baseline; Activities of Daily Living (ADL) Domain.

The ADL domain includes 17 yes/no questions on four items (hygiene, dressing, continence, eating). Score equals number of questions answered yes multiplied by 100 divided by number of questions answered. Change: Mean ADL score at observation minus mean ADL score at baseline.

Time frame:
Baseline, week 12, week 24
Reported as:
Mean · score on a scale
Disability Assessment for Dementia Change From Baseline; Activities of Daily Living (ADL) Domain.
score on a scaleDonepezil
week 12 (n=124)1.68 ± 13.23
week 24 (n=114)-1.61 ± 19.68
week 24 LOCF (n=137)-1.88 ± 18.15
Statistical analysis
  • Donepezil · Mixed Models Analysis · p = 0.218 · Mean difference (net): 2.0 · 95% CI -1.20 to 5.19
  • Donepezil · Mixed Models Analysis · p = 0.385 · Median difference (net): -1.85 · 95% CI -6.03 to 2.34
  • Donepezil · Mixed Models Analysis · p = 0.228
SecondaryDisability Assessment for Dementia Change From Baseline; Instrumental ADL (IADL) Domain.

IADL domain consists of 23 yes-no questions on 6 items (meal preparation, telephoning, going out, finance \& correspondence, medications, leisure \& housework. Change: Mean IADL score at observation minus mean IADL score at baseline. Total IADL score = number of questions answered yes multiplied by 100 divided by total number of questions answered

Time frame:
Baseline, 12 weeks, 24 weeks
Reported as:
Mean · score on a scale
Disability Assessment for Dementia Change From Baseline; Instrumental ADL (IADL) Domain.
score on a scaleDonepezil
week 12 (n=124)1.68 ± 18.01
week 24 (n=114)0.20 ± 22.37
week 24 LOCF (n=137)1.31 ± 22.30
Statistical analysis
  • Donepezil · Mixed Models Analysis · p = 0.404 · Mean difference (net): 1.84 · 95% CI -2.51 to 6.18
  • Donepezil · Mixed Models Analysis · p = 0.826 · Mean difference (net): 0.57 · 95% CI -4.51 to 5.64
  • Donepezil · Mixed Models Analysis · p = 0.494
SecondaryDisability Assessment for Dementia (DAD) Change From Baseline Total Score; Full Analysis Set (FAS)

DAD total score equals total number of questions answered yes multiplied by 100 divided by total number of questions answered.

Time frame:
Baseline, week 12, week 24
Reported as:
Mean · score on a scale
Disability Assessment for Dementia (DAD) Change From Baseline Total Score; Full Analysis Set (FAS)
score on a scaleDonepezil
week 12 (n=124)1.71 ± 13.18
week 24 (n=114)-0.12 ± 18.01
week 24 LOCF (n=137)0.17 ± 17.01
Statistical analysis
  • Donepezil · Mixed Models Analysis · p = 0.272 · Mean difference (net): 1.78 · 95% CI -1.42 to 4.99
  • Donepezil · Mixed Models Analysis · p = 0.894 · Mean difference (net): -0.27 · 95% CI -4.21 to 3.68
  • Donepezil · Mixed Models Analysis · p = 0.906
SecondaryFree-hand Drawing Test (CLOX 1) Change From Baseline; Full Analysis Set (FAS)

The ability to draw a clock free-hand. Scored on a scale from 1 to 15; lower scores indicate higher impairment. Change: Mean CLOX 1 score at observation minus mean CLOX score at baseline.

Time frame:
Baseline, 12 weeks, 24 weeks
Reported as:
Mean · Score on a scale
Free-hand Drawing Test (CLOX 1) Change From Baseline; Full Analysis Set (FAS)
Score on a scaleDonepezil
Week 12 (n=123)-0.03 ± 3.08
Week 24 (n=111)0.95 ± 3.13
Week LOCF (n=137)0.74 ± 3.13
Statistical analysis
  • Donepezil · Mixed Models Analysis · p = 0.719 · Mean difference (net): 0.13 · 95% CI -0.56 to 0.82
  • Donepezil · Mixed Models Analysis · p = 0.006 · Median difference (net): 1.00 · 95% CI 0.29 to 1.71
  • Donepezil · Mixed Models Analysis · p = 0.007
SecondaryCopied Clock Drawing Test (CLOX 2) Change From Baseline; Full Analysis Set (FAS)

The ability to copy a drawing of a clock. Scored on a scale from 1 to 15; lower scores indicate higher impairment. Change: Mean CLOX 2 score at observation minus mean CLOX 2 score at baseline.

Time frame:
Baseline, 12 weeks, 24 weeks
Reported as:
Mean · Score on scale
Copied Clock Drawing Test (CLOX 2) Change From Baseline; Full Analysis Set (FAS)
Score on scaleDonepezil
week 12 (n=117)0.28 ± 3.35
week 24 (n=106)0.84 ± 2.92
week 24 LOCF (n=131)0.51 ± 3.09
Statistical analysis
  • Donepezil · Mixed Models Analysis · p = 0.368 · Mean difference (net): 0.32 · 95% CI -0.38 to 1.01
  • Donepezil · Mixed Models Analysis · p = 0.030 · Mean difference (net): 0.72 · 95% CI 0.07 to 1.37
  • Donepezil · Mixed Models Analysis · p = 0.060
SecondaryCLOX Differential Score Change From Baseline; Full Analysis Set (FAS)

CLOX differential score equals the difference between the score for CLOX 2 and the score for CLOX 1, values range from 15 to 0, with 0 indicating perfect executive function, and a worsening with the increasing score.

Time frame:
Baseline, 12 weeks, 24 weeks
Reported as:
Mean · Score on a scale
CLOX Differential Score Change From Baseline; Full Analysis Set (FAS)
Score on a scaleDonepezil
week 12 (n=117)0.26 ± 3.50
week 24 (n=106)-0.35 ± 3.31
week 24 LOCF (n=131)-0.44 ± 3.36
Statistical analysis
  • Donepezil · Mixed Models Analysis · p = 0.516 · Mean difference (net): 0.21 · 95% CI -0.44 to 0.86
  • Donepezil · Mixed Models Analysis · p = 0.297 · Mean difference (net): -0.34 · 95% CI -0.97 to 0.30
  • Donepezil · Mixed Models Analysis · p = 0.133
SecondaryPhonectic Fluency Total Score From Baseline; Full Analysis Set (FAS)

The number of words a particpant can generate in 1 minute.

Time frame:
Baseline, 12 weeks, week 24
Reported as:
Mean · score on scale
Phonectic Fluency Total Score From Baseline; Full Analysis Set (FAS)
score on scaleDonepezil
week 12 (n=123)0.84 ± 2.85
week 24 (n=113)0.92 ± 3.38
week 24 LOCF (n=136)0.83 ± 3.29
Statistical analysis
  • Donepezil · Mixed Models Analysis · p = 0.020 · Median difference (net): 0.79 · 95% CI 0.13 to 1.45
  • Donepezil · Mixed Models Analysis · p = 0.018 · Median difference (net): 0.87 · 95% CI 0.16 to 1.59
  • Donepezil · Mixed Models Analysis · p = 0.004
SecondaryNeuropsychiatric Inventory Questionnaire (NPI-Q) Score Change From Baseline; Full Analysis Set (FAS)

NPI-Q measures severity of behavioural manifestations of dementia \& the level of distress each symptom gives the main caregiver, 1 (mild), 3 (severe), 0 if symptom absent, NPI-Q also measures the caregiver distress associated with each symptom,0(no distress)to 5(very severe), total score equals sum of individual item scores \& ranges from 0 to 36

Time frame:
Baseline, 12 weeks, 24 weeks
Reported as:
Mean · Score on scale
Neuropsychiatric Inventory Questionnaire (NPI-Q) Score Change From Baseline; Full Analysis Set (FAS)
Score on scaleDonepezil
week 12 (n=124)-1.06 ± 4.02
week 24 (n=114)-1.20 ± 4.19
week 24 LOCF (n=137)-1.19 ± 4.03
Statistical analysis
  • Donepezil · Mixed Models Analysis · p = 0.010 · Mean difference (net): -1.10 · 95% CI -1.93 to -0.27
  • Donepezil · Mixed Models Analysis · p = 0.018 · Mean difference (net): -1.12 · 95% CI -2.05 to -0.19
  • Donepezil · Mixed Models Analysis · p = 0.018
SecondaryNeuropsychiatric Inventory Questionnaire Distress (NPI-Q-D) Score Change From Baseline; Full Analysis Set (FAS)

The total NPI-Q-D score is equal to the sum of all indiviudal symptom distress scale scores with a range of 0 to 60

Time frame:
Baseline, week 12, week 24
Reported as:
Mean · Score on a scale
Neuropsychiatric Inventory Questionnaire Distress (NPI-Q-D) Score Change From Baseline; Full Analysis Set (FAS)
Score on a scaleDonepezil
week 12 (n=124)-0.95 ± 5.54
week 24 (n=114)-1.37 ± 6.25
week 24 LOCF (n=137)-1.08 ± 6.04
Statistical analysis
  • Donepezil · Mixed Models Analysis · p = 0.182 · Mean difference (net): -0.83 · 95% CI -2.06 to 0.39
  • Donepezil · Mixed Models Analysis · p = 0.114 · Mean difference (net): -1.09 · 95% CI -2.44 to 0.26
  • Donepezil · Mixed Models Analysis · p = 0.038
SecondaryClinical Global Impressions Severity Score (CGI-S) Clinical Global Impressions Severity Score Improvement(CGI-I)Change From Baseline, Full Analysis Set (FAS)

Scale measures subject's clinical condition at baseline for severity (CGI-S) \& for improvement from baseline (CGI-I). At baseline subject rated on numerical scale, 1 (not at all ill) to 7 (most extremely ill). At follow up subject rated on 7 point Likert scale from 1(very much improved) to 7(very much worse) \& 4 indicates no change from baseline

Time frame:
Baseline, week 24
Reported as:
Mean · Score on a scale
Clinical Global Impressions Severity Score (CGI-S) Clinical Global Impressions Severity Score Improvement(CGI-I)Change From Baseline, Full Analysis Set (FAS)
Score on a scaleDonepezil
Baseline (n=136)3.40 ± 0.67
Week 24 (n=116)3.32 ± 1.21
Week 24 LOCF (n=136)3.40 ± 1.19
SecondaryClinical Global Impressions Severity (CGI-S)

Scale measures subject's clinical condition at baseline for severity (CGI-S) subject rated on numerical scale, 1 (not at all ill) to 7 (most extremely ill).

Time frame:
Baseline
Reported as:
Number · Participants
Clinical Global Impressions Severity (CGI-S)
ParticipantsDonepezil
Normal, not at all ill (n=136)2
Borderline mentally ill (n=136)4
Mildly ill (n=136)72
Moderately ill (n=136)54
Markedly ill (n=136)4
Severely ill (n=136)0
Among the most extremely ill patients (n=136)0
SecondaryClinical Global Impressions Improvement (CGI-I)

Scale measures subject's clinical condition for improvement from baseline (CGI-I)subject rated on 7 point Likert scale from 1(very much improved) to 7(very much worse) \& 4 indicates no change from baseline

Time frame:
Week (wk) 24
Reported as:
Number · Participants
Clinical Global Impressions Improvement (CGI-I)
ParticipantsDonepezil
Wk 24 Very much improved (n=116)3
Wk 24 Much improved (n=116)27
Wk 24 Minimally improved (n=116)44
Wk 24 No change (n=116)21
Wk 24 Minimally worse (n=116)14
Wk 24 Much worse (n=116)7
Wk 24 Very much worse (n=116)0
Wk 24 LOCF Very much improved (n=136)4
Wk 24 LOCF Much improved (n=136)27
Wk 24 LOCF Minimally improved (n=136)49
Wk 24 LOCF No change (n=136)30
Wk 24 LOCF Minimally worse (n=136)19
Wk 24 LOCF Much worse (n=136)7
Wk 24 LOCF Very much worse (n=136)0
SecondaryClinical Global Impressions Improvement (CGI-I) Dichotomized Response

Scale measures subject's (CGI-I) rated on categorial 7 point Likert scale 1 (very much improved) to 7 (very much worse) with 4 indicating no change from baseline. A dichotomized variable was created: responder = CGI-I score of 4 or less; non-responder = CGI-I score of 5 or more

Time frame:
Baseline, week 24
Reported as:
Number · Particpants
Clinical Global Impressions Improvement (CGI-I) Dichotomized Response
ParticpantsDonepezil
Week 24 Responder (n=116)95
Week 24 Non-responder (n=116)21
Week 24 LOCF Responder (n=136)110
Week 24 LOCF Non-responder (n=136)26

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Donepezil———
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventDonepezil
Hip fractureInjury, poisoning and procedural complications3/148
Myocardial infarctionCardiac disorders2/148
Chest painGeneral disorders2/148
UrosepsisInfections and infestations2/148
Cerebrovascular accidentNervous system disorders2/148
Cardiac failure congestiveCardiac disorders1/148
Sick sinus syndromeCardiac disorders1/148
Abdominal painGastrointestinal disorders1/148
Duodenal ulcerGastrointestinal disorders1/148
General physical health deteriorationGeneral disorders1/148
Most frequent other events
Most frequent other events
EventDonepezil
NauseaGastrointestinal disorders26/148
DiarrhoeaGastrointestinal disorders15/148
InsomniaPsychiatric disorders15/148
DizzinessNervous system disorders11/148
VomitingGastrointestinal disorders9/148
AnorexiaMetabolism and nutrition disorders8/148
HeadacheNervous system disorders8/148

Baseline characteristics

Age, Customized
Age, Customized(Participants)Donepezil
< 450
45-6420
>= 65129
Sex: Female, Male
Sex: Female, Male(Participants)Donepezil
Female82
Male67
08

Study locations

30 sites
  • Pfizer Investigational Site
    Belvedere, Alberta T5C 0A3, Canada
  • Pfizer Investigational Site
    Edmonton, Alberta T5A 4L8, Canada
  • Pfizer Investigational Site
    Edmonton, Alberta T6A 0A5, Canada
  • Pfizer Investigational Site
    Abbotsford, British Columbia V2S 3P8, Canada
  • Pfizer Investigational Site
    Coquitlam, British Columbia V3K 3P4, Canada
  • Pfizer Investigational Site
    Victoria, British Columbia V8T 5G1, Canada
  • Pfizer Investigational Site
    Winnipeg, Manitoba R2H 0R8, Canada
  • Pfizer Investigational Site
    Saint John, New Brunswick E2L 3L6, Canada
  • Pfizer Investigational Site
    Amherst, Nova Scotia B4H 4R7, Canada
  • Pfizer Investigational Site
    Halifax, Nova Scotia B3H 2E1, Canada
  • Pfizer Investigational Site
    Pictou, Nova Scotia B0K 1H0, Canada
  • Pfizer Investigational Site
    Burlington, Ontario L7M 4Y1, Canada
  • Pfizer Investigational Site
    Corunna, Ontario N0N 1G0, Canada
  • Pfizer Investigational Site
    Fort Erie, Ontario L2A 1Z3, Canada
  • Pfizer Investigational Site
    Hawkesbury, Ontario K6A 1A1, Canada
  • Pfizer Investigational Site
    North Bay, Ontario P1B 2H3, Canada
  • Pfizer Investigational Site
    Ottawa, Ontario K1N 5C8, Canada
  • Pfizer Investigational Site
    Ottawa, Ontario K2C 3R2, Canada
  • Pfizer Investigational Site
    Ottawa, Ontario K2G 3Y5, Canada
  • Pfizer Investigational Site
    Peterborough, Ontario K9H 2P4, Canada
  • Pfizer Investigational Site
    Sarnia, Ontario N7T 4X3, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M3B 2W7, Canada
  • Pfizer Investigational Site
    Beauport, Quebec G1J 2G3, Canada
  • Pfizer Investigational Site
    Cowansville, Quebec J2K 2X9, Canada
  • Pfizer Investigational Site
    L'Ancienne-Lorette, Quebec G2E 2X1, Canada
  • Pfizer Investigational Site
    Montréal, Quebec H1T 2M4, Canada
  • Pfizer Investigational Site
    Rimouski, Quebec G5L 9A8, Canada
  • Pfizer Investigational Site
    St-Jean-sur-Richelieu, Quebec J2W 2A3, Canada
  • Pfizer Investigational Site
    St. Leonard, Quebec H1S 3A9, Canada
  • Pfizer Investigational Site
    Regina, Saskatchewan S4P 3X1, Canada
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2005, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2009, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2005
First posted
Sep 15, 2005
Start
Jun 2005
Primary completionActual
Apr 2008
CompletionActual
Apr 2008
Results first posted
Jun 12, 2009
Last update
Mar 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00174382
Lead sponsor
Pfizer
First posted
Sep 15, 2005
Start date
Jun 2005
Primary completion
Apr 2008
Completion
Apr 2008
Results posted
Jun 12, 2009
Last update
Mar 24, 2015

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion